TEMOkids Study : A Phase I Pediatric Study for KIMOZO, Oral Suspension of Temozolomide

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

49 participants

Study Classification

INTERVENTIONAL

Study Start Date

2021-03-16

Study Completion Date

2023-07-03

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Non-randomized, international, multi-centre, open-label, single arm study to determine the pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide (KIMOZO) in the pediatric population aged 1 year and over.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Temozolomide in Treating Young Patients With High-Risk Relapsed or Refractory Neuroblastoma

NCT00276679

Neuroblastoma

COMPLETED PHASE2

Temozolomide in Association With Topotecan in Refractory or Relapsed Malignant Tumors in Children and Adolescents

NCT00412503

Refractory Tumors Malignant Tumors

COMPLETED PHASE1

Proof -of -Concept Study To Stratify Targeted Therapies Adapted To Molecular Profiling

NCT02613962

Relapsed or Refractory Pediatric Tumor

UNKNOWN NA

Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors

NCT00020150

Brain and Central Nervous System Tumors Childhood Germ Cell Tumor Extragonadal Germ Cell Tumor +6 more

COMPLETED PHASE1

Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia

NCT00083070

Leukemia

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The TEMOkids study is an international open-label, non-randomized, prospective, single-arm phase 1 study to determine the pharmacokinetic (PK) parameters of a single dose of an oral suspension of temozolomide (KIMOZO) in the pediatric population aged 1 year and over.

Patients will be subject to at least one 21 or 28-day treatment cycle involving administration of an oral suspension of temozolomide (KIMOZO) for five consecutive days followed by 16 or 23-days resting period, with determination of the PK parameters on the first treatment day.

Five (5) additional cycles will be allowed under compassionate use regimen. The compassionate use period could be extended at the discretion of the investigator and in agreement with the sponsor. Safety and activity data will be collected during the compassionate follow-up period.

The study will be held in multiple sites spread across Europe.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pediatric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Non-randomized, international, multi-centre, open-label, single arm study

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Single arm

Temozolomide 40 mg/ml, Oral suspension

Group Type EXPERIMENTAL

Temozolomide Oral Suspension

Intervention Type DRUG

One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Temozolomide Oral Suspension

One prescribed oral dose (range 75 to 200 mg/m2) once daily for 5 days

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

KIMOZO, Ped-TMZ

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Pediatric patients in need of temozolomide (all indications with 5-day treatment per 21- or 28-day cycle).
* Male and female patients aged 1 to less than 18 years
* Patients who have signed the informed consent or for which one, both parents or legal guardian (depending on local legislation) have signed the informed consent.
* Patients having records of coverage by a health insurance
* Life expectancy ≥ 3 months
* Adequate haematological function:

* haemoglobin ≥ 80 g/L (transfusion support authorized)
* neutrophil count ≥ 1.0 x 10e9 cells/L
* platelet count ≥ 100 x 10e9 cells/L (without transfusion support)
* in case of bone marrow involvement: neutrophils ≥ 0.5 x 10e9 cells/L and platelets ≥75 x 10e9 cells/L
* Adequate renal function:

* Creatine clearance ≥ 60 mL/min.1.73m² according to the Schwartz formula \[1\] or its modified form \[2\]
* Adequate hepatic function:

* bilirubin ≤1.5 x ULN
* AST and ALT ≤ 2.5 x ULN (AST, ALT 5xULN in case of liver metastases)
* Lansky Score ≥ 70%

Exclusion Criteria

* Patients who are co-administrated at day one with sodium valproate as it decreases the clearance of temozolomide
* Patients with (naso)gastric tube administration of temozolomide during first cycle of treatment.
* Patients already enrolled in studies investigating temozolomide or other investigational new drugs.
* A post-menarche female with a positive blood/urine pregnancy test at inclusion.
* Known contraindication or hypersensitivity to temozolomide or any chemically close substance

Minimum Eligible Age

1 Year

Maximum Eligible Age

17 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No